[go: up one dir, main page]

MX2020004674A - Anticuerpos contra alfa-sinucleina y usos de los mismos. - Google Patents

Anticuerpos contra alfa-sinucleina y usos de los mismos.

Info

Publication number
MX2020004674A
MX2020004674A MX2020004674A MX2020004674A MX2020004674A MX 2020004674 A MX2020004674 A MX 2020004674A MX 2020004674 A MX2020004674 A MX 2020004674A MX 2020004674 A MX2020004674 A MX 2020004674A MX 2020004674 A MX2020004674 A MX 2020004674A
Authority
MX
Mexico
Prior art keywords
synuclein
antibodies
aggregates
antibody
diagnosis
Prior art date
Application number
MX2020004674A
Other languages
English (en)
Inventor
Jinhyung Ahn
Sungwon An
Dongin Kim
Jaehyun Eom
Weonkyoo You
Jinwon Jung
Yeunju Kim
Yonggyu Son
Byungje Sung
Sang Hoon Lee
Bora Lee
Seawon Ahn
Youngdon Pak
Donghoon Yeom
Daehae Song
Original Assignee
Abl Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abl Bio Inc filed Critical Abl Bio Inc
Publication of MX2020004674A publication Critical patent/MX2020004674A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención proporciona un anticuerpo anti-a-sinucleína que de manera preferencial reconoce agregados de a-sinucleína, y uso de detección, diagnóstico y/o tratamiento o prevención de diversas enfermedades causadas por acumulación de agregados de a-sinucleína y sus enfermedades de síntomas relacionadas usando el anticuerpo anti-a-sinucleína.
MX2020004674A 2017-11-17 2018-11-16 Anticuerpos contra alfa-sinucleina y usos de los mismos. MX2020004674A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762588018P 2017-11-17 2017-11-17
US201862687848P 2018-06-21 2018-06-21
PCT/KR2018/014123 WO2019098763A2 (ko) 2017-11-17 2018-11-16 알파-시누클레인에 대한 항체 및 그 용도

Publications (1)

Publication Number Publication Date
MX2020004674A true MX2020004674A (es) 2020-08-13

Family

ID=66537805

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020004674A MX2020004674A (es) 2017-11-17 2018-11-16 Anticuerpos contra alfa-sinucleina y usos de los mismos.
MX2025011654A MX2025011654A (es) 2017-11-17 2020-07-13 Anticuerpos contra alfa sinucleina y usos de los mismos

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025011654A MX2025011654A (es) 2017-11-17 2020-07-13 Anticuerpos contra alfa sinucleina y usos de los mismos

Country Status (10)

Country Link
US (1) US20230279085A1 (es)
EP (1) EP3725802A4 (es)
JP (2) JP7173618B2 (es)
KR (1) KR102508933B1 (es)
CN (1) CN111356701B (es)
AU (3) AU2018370279B2 (es)
BR (1) BR112020009707A2 (es)
CA (1) CA3082559A1 (es)
MX (2) MX2020004674A (es)
WO (1) WO2019098763A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110494445B (zh) * 2017-01-06 2023-10-20 Abl生物公司 抗α-SYN抗体及其用途
EP3567054A4 (en) * 2017-01-06 2021-03-10 ABL Bio Inc. ANTI-ALPHA SYN ANTIBODIES AND USES THEREOF
WO2018151821A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
MX2020004674A (es) * 2017-11-17 2020-08-13 Abl Bio Inc Anticuerpos contra alfa-sinucleina y usos de los mismos.
CA3085572A1 (en) 2017-12-14 2019-06-20 Abl Bio Inc. Bispecific antibody to a-syn/igf1r and use thereof
EP3985022A4 (en) * 2019-06-14 2023-08-02 ABL Bio, Inc. BISPECIFIC ANTIBODIES AGAINST A-SYN/IGF1R AND ITS USE
EP4229082A1 (en) * 2020-10-16 2023-08-23 AC Immune SA Antibodies binding to alpha-synuclein for therapy and diagnosis
WO2022238961A1 (en) * 2021-05-12 2022-11-17 Abl Bio Incorporated Antibodies for treating alpha-synucleinopathies
CN113912714B (zh) * 2021-12-15 2022-02-22 北京凯祥弘康生物科技有限公司 特异性结合α-突触核蛋白的抗体及其应用
CN113912713B (zh) * 2021-12-15 2022-03-08 北京凯祥弘康生物科技有限公司 一种抗α-突触核蛋白的单克隆抗体及其应用
JP2025528390A (ja) * 2022-08-24 2025-08-28 ザ・リサーチ・ファンデーション・フォー・ザ・ステート・ユニバーシティ・オブ・ニューヨーク 抗モノメチルアウリスタチン抗体および抗体フラグメント
CN117607463B (zh) * 2024-01-23 2024-04-09 杭州华得森生物技术有限公司 一种循环肿瘤细胞egfr免疫显色检测试剂
CN120446488B (zh) * 2025-07-08 2025-09-12 杭州华得森生物技术有限公司 用于多重免疫检测的试剂盒及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP5810413B2 (ja) 2008-12-19 2015-11-11 バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー ヒト抗アルファシヌクレイン自己抗体
DK2539366T3 (en) 2010-02-26 2018-02-05 Bioarctic Neuroscience Ab PROTOFIBRIL-BINDING ANTIBODIES AND THEIR USE IN THERAPEUTIC AND DIAGNOSTIC PROCEDURES FOR PARKINSON'S DISEASE, DEMENS WITH LEWY BODY AND OTHER ALPHA SYNUCLEINOPATHIES
EP2366714A1 (en) * 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
HUE041391T2 (hu) * 2011-06-23 2019-05-28 Biogen Int Neuroscience Gmbh Anti-alfa-szinukleinkötõ molekulák
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
GB201512203D0 (en) * 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
EP3567054A4 (en) * 2017-01-06 2021-03-10 ABL Bio Inc. ANTI-ALPHA SYN ANTIBODIES AND USES THEREOF
CN110494445B (zh) * 2017-01-06 2023-10-20 Abl生物公司 抗α-SYN抗体及其用途
MX2020004674A (es) * 2017-11-17 2020-08-13 Abl Bio Inc Anticuerpos contra alfa-sinucleina y usos de los mismos.
CA3085572A1 (en) * 2017-12-14 2019-06-20 Abl Bio Inc. Bispecific antibody to a-syn/igf1r and use thereof

Also Published As

Publication number Publication date
MX2025011654A (es) 2025-11-03
US20230279085A1 (en) 2023-09-07
AU2022252753B2 (en) 2025-06-05
WO2019098763A9 (ko) 2019-08-29
EP3725802A4 (en) 2021-08-11
JP7173618B2 (ja) 2022-11-16
AU2025226709A1 (en) 2025-09-25
BR112020009707A2 (pt) 2020-10-13
AU2022252753A1 (en) 2023-01-19
CA3082559A1 (en) 2019-05-23
WO2019098763A3 (ko) 2019-07-11
AU2018370279A1 (en) 2020-05-28
WO2019098763A2 (ko) 2019-05-23
CN111356701A (zh) 2020-06-30
EP3725802A2 (en) 2020-10-21
CN111356701B (zh) 2023-11-21
JP2023017837A (ja) 2023-02-07
AU2018370279B2 (en) 2022-11-03
KR102508933B1 (ko) 2023-03-13
JP2021503288A (ja) 2021-02-12
KR20190057004A (ko) 2019-05-27
JP7610279B2 (ja) 2025-01-08

Similar Documents

Publication Publication Date Title
MX2025011654A (es) Anticuerpos contra alfa sinucleina y usos de los mismos
BR112018016697A2 (pt) anticorpo revestido, quimérico ou humanizado, composição farmacêutica, e, método de tratamento.
MX2021011167A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
CL2021000736A1 (es) Receptor de antígeno quimérico.
CL2017003195A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso.
CO2017000754A2 (es) Anticuerpo monoclonal anti-ctla4 o fragmento de unión a antígeno del mismo, y una composición farmacéutica del mismo
BR112021004316A2 (pt) Anticorpos de agonistas anti-trem-2
MX2024006564A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
CO2017006740A2 (es) Anticuerpos anti–cd79b
IL271266A (en) Use of anti cd70 antibody argx-110 to treat acute myeloid leukaemia
BR112018014016A2 (pt) combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer
MX374853B (es) Anticuerpos anti-proteína que contiene domino de inmunologlubina relacionado con el receptor de poliovirus (pvrig) y metodos de uso.
MX389289B (es) Formulación farmacéutica acuosa que comprende el anticuerpo anti receptor de muerte programada l1 (pd-l1) avelumab.
MX2017000419A (es) Anticuerpos anti-pd-l1 y sus usos de diagnóstico.
MX377844B (es) Anticuerpos anti proteína relacionada con el receptor del factor de necrosis tumoral inducida por glucocorticóides (gitr) y sus métodos de uso.
AR101846A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
BR112013020500A8 (pt) anticorpo isolado, recombinante ou purificado
MX2022015250A (es) Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.
EA201991464A1 (ru) АНТИТЕЛО К α-СИНУКЛЕИНУ И ЕГО ПРИМЕНЕНИЕ
BR112016014731A2 (pt) Anticorpos anti-baff
MX2018012493A (es) Métodos para controlar y tratar el cáncer.
ECSP19018327A (es) Anticuerpo que se une específicamente a pd-1 y fragmento funcional del mismo
BR112019004990A2 (pt) anticorpo que se liga especificamente a il-17a e fragmento funcional do mesmo
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.